CNS Diseases

A clinical-stage biotech asked Health Advances to perform a broad assessment of CNS and ophthalmology disorders for the client's proprietary drug discovery platform. The team evaluated and prioritized indications across technical, developmental, commercial, and strategic criteria to produce a prioritized list for deeper research. We incorporated top indications into near- and long-term strategic roadmaps to guide the client's portfolio expansion strategy.

Health Advances was engaged by a venture-backed, clinical-stage biopharma with a data-science platform in the CNS space to develop a corporate strategy. We worked closely with the management team to perform a situation analysis, identify key market and competitive trends, and develop a decision tree to inform portfolio priorities in different scenarios. Our work provided a vision for how the company could create value and underpinned the strategic guidance that management provided to investors, leading to a successful financing.

Health Advances worked with a biotech developing novel measurement tools for multiple sclerosis to define a product strategy. We evaluated the MS drug landscape, understood biopharma needs, explored the competitive landscape and identified the most promising opportunities for the client to unlock value. The team's work enabled our client to prioritize product development investments and partnership activities.

A global biopharma company needed a go-to-market strategy for a digital therapeutic in development for a psychiatric disorder. The team performed an in-depth evaluation of the competitive, reimbursement, health policy, and market landscape and distilled strategic insights from the launch experience of competitive and adjacent DTx products. We collaborated with the client to weigh trade-offs across go-to-market approaches and developed an actionable strategy that fit the client’s needs and capabilities. 

A life science tools company wanted to explore opportunities in the clinical diagnostics space with their differentiated protein detection technology. Our team developed comprehensive primers on key diagnostics markets and business models, including specialty CLIA lab services, clinical lab instrumentation and reagents, and point-of-care. We also conducted an in-depth evaluation of the commercial opportunity for the technology in a specific CNS disease. Finally, we worked closely with the management team to articulate their strategy and develop an operating plan for the coming year that would advance their objectives. Our client used our work to guide activities and initiatives and they shared it with their board to inform their decision regarding the clinical diagnostics opportunity.

Working with a biotech company with key pipeline investments in Alzheimer's Disease, Health Advances analyzed the future impact of blood biomarkers on the patient diagnostic journey. Our team conducted a large global interview program across the US, China, Japan, Brazil, and the EU to understand current views, future expectations, and anticipated challenges for blood biomarker implementation. We then distilled the key strategic implications for our client's portfolio and commercialization plans. These insights anchored our client's decision to pursue partnerships and data development.

Health Advances was engaged by a company with a high-sensitivity technology to provide an update to its clinical diagnostics strategy in the CNS space. The team conducted in depth interviews with clinicians, payers, and industry experts and secondary research reviewing clinical literature and industry analogs in order to validate the most attractive scenarios for test menu and entrance into clinical diagnostics. Additionally, the team evaluated analog companies to demonstrate how significant value can be generated for shareholders through clinical diagnostics business models. To complete the work, the team updated the P&L from a previous engagement to provide a financial perspective on the recommended strategy.